Equities Analysts Offer Predictions for biote Q1 Earnings

biote Corp. (NASDAQ:BTMD) – Research analysts at Roth Capital decreased their Q1 2025 earnings per share estimates for biote in a note issued to investors on Thursday, March 13th. Roth Capital analyst G. Kelly now expects that the company will earn $0.09 per share for the quarter, down from their previous estimate of $0.13. The consensus estimate for biote’s current full-year earnings is $0.75 per share. Roth Capital also issued estimates for biote’s Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $0.53 EPS and FY2026 earnings at $0.70 EPS.

Separately, Craig Hallum dropped their price target on biote from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday.

biote Stock Up 22.5 %

Shares of BTMD stock opened at $3.76 on Friday. biote has a fifty-two week low of $3.04 and a fifty-two week high of $8.44. The stock has a market cap of $204.31 million, a P/E ratio of 14.46 and a beta of 1.07. The business has a fifty day simple moving average of $4.96 and a 200-day simple moving average of $5.55.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio acquired a new stake in shares of biote during the fourth quarter valued at $69,000. Squarepoint Ops LLC acquired a new stake in shares of biote during the fourth quarter valued at $115,000. Millennium Management LLC acquired a new stake in shares of biote during the fourth quarter valued at $414,000. Lazard Asset Management LLC acquired a new stake in shares of biote during the fourth quarter valued at $139,000. Finally, Deutsche Bank AG boosted its stake in shares of biote by 4,987.5% during the fourth quarter. Deutsche Bank AG now owns 31,441 shares of the company’s stock valued at $194,000 after acquiring an additional 30,823 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.